Why the study?
Does rofecoxib alter the risk of thromboembolic events compared to meloxicam in general practice patients?
Does rofecoxib alter the risk of thromboembolic events compared to meloxicam in general practice patients?
In a general practice cohort, rofecoxib was associated with an increased risk of cerebrovascular thromboembolic events but a decreased risk of peripheral venous thrombotic events compared to meloxicam.
No takes yet. Share an insight, caveat, or question.
May warrant cerebrovascular caution with rofecoxib in practice; leaves open causality and generalizability beyond this cohort.
Deborah Layton (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: